172 related articles for article (PubMed ID: 21360561)
1. Lobe-specific lineages of carcinogenesis in the transgenic adenocarcinoma of mouse prostate and their responses to chemopreventive selenium.
Wang L; Zhang J; Zhang Y; Nkhata K; Quealy E; Liao JD; Cleary MP; Lü J
Prostate; 2011 Sep; 71(13):1429-40. PubMed ID: 21360561
[TBL] [Abstract][Full Text] [Related]
2. Chemoprevention of prostate carcinogenesis by alpha-difluoromethylornithine in TRAMP mice.
Gupta S; Ahmad N; Marengo SR; MacLennan GT; Greenberg NM; Mukhtar H
Cancer Res; 2000 Sep; 60(18):5125-33. PubMed ID: 11016639
[TBL] [Abstract][Full Text] [Related]
3. Chemopreventive Effects of Korean Angelica versus Its Major Pyranocoumarins on Two Lineages of Transgenic Adenocarcinoma of Mouse Prostate Carcinogenesis.
Tang SN; Zhang J; Wu W; Jiang P; Puppala M; Zhang Y; Xing C; Kim SH; Jiang C; Lü J
Cancer Prev Res (Phila); 2015 Sep; 8(9):835-44. PubMed ID: 26116406
[TBL] [Abstract][Full Text] [Related]
4. Efficacious chemoprevention of primary prostate cancer by flutamide in an autochthonous transgenic model.
Raghow S; Kuliyev E; Steakley M; Greenberg N; Steiner MS
Cancer Res; 2000 Aug; 60(15):4093-7. PubMed ID: 10945615
[TBL] [Abstract][Full Text] [Related]
5. Malignancy arising in seminal vesicles in the transgenic adenocarcinoma of mouse prostate (TRAMP) model.
Yeh IT; Reddick RL; Kumar AP
Prostate; 2009 May; 69(7):755-60. PubMed ID: 19170049
[TBL] [Abstract][Full Text] [Related]
6. Characterization of the autochthonous transgenic adenocarcinoma of the mouse prostate (TRAMP) as a model to study effects of castration therapy.
Wikström P; Lindahl C; Bergh A
Prostate; 2005 Feb; 62(2):148-64. PubMed ID: 15389804
[TBL] [Abstract][Full Text] [Related]
7. Androgen-independent prostate cancer progression in the TRAMP model.
Gingrich JR; Barrios RJ; Kattan MW; Nahm HS; Finegold MJ; Greenberg NM
Cancer Res; 1997 Nov; 57(21):4687-91. PubMed ID: 9354422
[TBL] [Abstract][Full Text] [Related]
8. Methyl-selenium compounds inhibit prostate carcinogenesis in the transgenic adenocarcinoma of mouse prostate model with survival benefit.
Wang L; Bonorden MJ; Li GX; Lee HJ; Hu H; Zhang Y; Liao JD; Cleary MP; Lü J
Cancer Prev Res (Phila); 2009 May; 2(5):484-95. PubMed ID: 19401524
[TBL] [Abstract][Full Text] [Related]
9. A probasin-large T antigen transgenic mouse line develops prostate adenocarcinoma and neuroendocrine carcinoma with metastatic potential.
Masumori N; Thomas TZ; Chaurand P; Case T; Paul M; Kasper S; Caprioli RM; Tsukamoto T; Shappell SB; Matusik RJ
Cancer Res; 2001 Mar; 61(5):2239-49. PubMed ID: 11280793
[TBL] [Abstract][Full Text] [Related]
10. Dietary feeding of silibinin inhibits prostate tumor growth and progression in transgenic adenocarcinoma of the mouse prostate model.
Raina K; Blouin MJ; Singh RP; Majeed N; Deep G; Varghese L; Glodé LM; Greenberg NM; Hwang D; Cohen P; Pollak MN; Agarwal R
Cancer Res; 2007 Nov; 67(22):11083-91. PubMed ID: 18006855
[TBL] [Abstract][Full Text] [Related]
11. An investigation of the effects of late-onset dietary restriction on prostate cancer development in the TRAMP mouse.
Suttie AW; Dinse GE; Nyska A; Moser GJ; Goldsworthy TL; Maronpot RR
Toxicol Pathol; 2005; 33(3):386-97. PubMed ID: 15805078
[TBL] [Abstract][Full Text] [Related]
12. Genistein in the diet reduces the incidence of poorly differentiated prostatic adenocarcinoma in transgenic mice (TRAMP).
Mentor-Marcel R; Lamartiniere CA; Eltoum IE; Greenberg NM; Elgavish A
Cancer Res; 2001 Sep; 61(18):6777-82. PubMed ID: 11559550
[TBL] [Abstract][Full Text] [Related]
13. Toremifene prevents prostate cancer in the transgenic adenocarcinoma of mouse prostate model.
Raghow S; Hooshdaran MZ; Katiyar S; Steiner MS
Cancer Res; 2002 Mar; 62(5):1370-6. PubMed ID: 11888907
[TBL] [Abstract][Full Text] [Related]
14. Proteomic profiling of potential molecular targets of methyl-selenium compounds in the transgenic adenocarcinoma of mouse prostate model.
Zhang J; Wang L; Anderson LB; Witthuhn B; Xu Y; Lü J
Cancer Prev Res (Phila); 2010 Aug; 3(8):994-1006. PubMed ID: 20647336
[TBL] [Abstract][Full Text] [Related]
15. The chemopreventive action of catechins in the TRAMP mouse model of prostate carcinogenesis is accompanied by clusterin over-expression.
Caporali A; Davalli P; Astancolle S; D'Arca D; Brausi M; Bettuzzi S; Corti A
Carcinogenesis; 2004 Nov; 25(11):2217-24. PubMed ID: 15358631
[TBL] [Abstract][Full Text] [Related]
16. Characterization of prostatic epithelial cell lines derived from transgenic adenocarcinoma of the mouse prostate (TRAMP) model.
Foster BA; Gingrich JR; Kwon ED; Madias C; Greenberg NM
Cancer Res; 1997 Aug; 57(16):3325-30. PubMed ID: 9269988
[TBL] [Abstract][Full Text] [Related]
17. Regression of mouse prostatic intraepithelial neoplasia by nonsteroidal anti-inflammatory drugs in the transgenic adenocarcinoma mouse prostate model.
Narayanan BA; Narayanan NK; Pittman B; Reddy BS
Clin Cancer Res; 2004 Nov; 10(22):7727-37. PubMed ID: 15570007
[TBL] [Abstract][Full Text] [Related]
18. Loss of Nkx3.1 expression in the transgenic adenocarcinoma of mouse prostate model.
Bethel CR; Bieberich CJ
Prostate; 2007 Dec; 67(16):1740-50. PubMed ID: 17929276
[TBL] [Abstract][Full Text] [Related]
19. Broadening of transgenic adenocarcinoma of the mouse prostate (TRAMP) model to represent late stage androgen depletion independent cancer.
Jeet V; Ow K; Doherty E; Curley B; Russell PJ; Khatri A
Prostate; 2008 Apr; 68(5):548-62. PubMed ID: 18247402
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of prostate carcinogenesis in probasin/SV40 T antigen transgenic rats by raloxifene, an antiestrogen with anti-androgen action, but not nimesulide, a selective cyclooxygenase-2 inhibitor.
Zeng Y; Yokohira M; Saoo K; Takeuchi H; Chen Y; Yamakawa K; Matsuda Y; Kakehi Y; Imaida K
Carcinogenesis; 2005 Jun; 26(6):1109-16. PubMed ID: 15731164
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
